Researchers have uncovered new insights into the mechanisms behind severe schistosomiasis, focusing on how immune responses ...

WESTON, Fla. - ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a micro-cap biopharmaceutical company with a market capitalization of $1.82 million specializing in the development of treatments for renal and ...

The patient had had many antimicrobial, antiprotozoal, steroid and topical antibiotic treatments. The patient was misdiagnosed and treated for ... This area was biopsied, and the results were ...

Still, vaccines containing live virus should be avoided in MS patients who have weakened immune systems due to anti-inflammatory treatment, the guidelines note. “MS management changes on a ...

New insights into the mechanisms that cause more severe cases of schistosomiasis -- a disease caused by parasitic worms and second only to malaria in terms of potential harm -- have been revealed.

Optimal therapy for PID must take into consideration the severity of disease, the polymicrobial etiology of disease, the availability and costs of the antimicrobials, and their ease of administration.

Treatment of PID should take into account the short-term goals of clinical and microbiological cure and the long-term goals of prevention of infertility, ectopic pregnancy, recurrent infection and ...

The new product follows an EU approval in June for another Sanofi inflammation treatment, new rheumatoid arthritis treatment Kevzara (sarilumab). This makes the company a substantial player in ...

ZyVersa Therapeutics, a biopharmaceutical company focused on developing treatments for renal and inflammatory diseases, announced the issuance of a Shareholder Letter from CEO Stephen C.